Catharanthine Modulates Mesolimbic Dopamine Transmission and Nicotine Psychomotor Effects via Inhibition of α6-Nicotinic Receptors and Dopamine Transporters

ACS Chem Neurosci. 2024 May 1;15(9):1738-1754. doi: 10.1021/acschemneuro.3c00478. Epub 2024 Apr 13.

Abstract

Iboga alkaloids, also known as coronaridine congeners, have shown promise in the treatment of alcohol and opioid use disorders. The objective of this study was to evaluate the effects of catharanthine and 18-methoxycoronaridine (18-MC) on dopamine (DA) transmission and cholinergic interneurons in the mesolimbic DA system, nicotine-induced locomotor activity, and nicotine-taking behavior. Utilizing ex vivo fast-scan cyclic voltammetry (FSCV) in the nucleus accumbens core of male mice, we found that catharanthine or 18-MC differentially inhibited evoked DA release. Catharanthine inhibition of evoked DA release was significantly reduced by both α4 and α6 nicotinic acetylcholine receptors (nAChRs) antagonists. Additionally, catharanthine substantially increased DA release more than vehicle during high-frequency stimulation, although less potently than an α4 nAChR antagonist, which confirms previous work with nAChR antagonists. Interestingly, while catharanthine slowed DA reuptake measured via FSCV ex vivo, it also increased extracellular DA in striatal dialysate from anesthetized mice in vivo in a dose-dependent manner. Superfusion of catharanthine or 18-MC inhibited the firing rate of striatal cholinergic interneurons in a concentration dependent manner, which are known to potently modulate presynaptic DA release. Catharanthine or 18-MC suppressed acetylcholine currents in oocytes expressing recombinant rat α6/α3β2β3 or α6/α3β4 nAChRs. In behavioral experiments using male Sprague-Dawley rats, systemic administration of catharanthine or 18-MC blocked nicotine enhancement of locomotor activity. Importantly, catharanthine attenuated nicotine self-administration in a dose-dependent manner while having no effect on food reinforcement. Lastly, administration of catharanthine and nicotine together greatly increased head twitch responses, indicating a potential synergistic hallucinogenic effect. These findings demonstrate that catharanthine and 18-MC have similar, but not identical effects on striatal DA dynamics, striatal cholinergic interneuron activity and nicotine psychomotor effects.

Keywords: 18-methoxycoronaridine; Nicotine; addiction; catharanthine; dopamine; nicotinic acetylcholine receptors; nucleus accumbens core; self-administration; voltammetry.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Animals
  • Dopamine Plasma Membrane Transport Proteins* / drug effects
  • Dopamine Plasma Membrane Transport Proteins* / metabolism
  • Dopamine* / metabolism
  • Dose-Response Relationship, Drug
  • Ibogaine* / analogs & derivatives*
  • Ibogaine* / pharmacology
  • Interneurons / drug effects
  • Interneurons / metabolism
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Motor Activity / drug effects
  • Nicotine* / pharmacology
  • Nicotinic Agonists / pharmacology
  • Nicotinic Antagonists / pharmacology
  • Nucleus Accumbens / drug effects
  • Nucleus Accumbens / metabolism
  • Oocytes / drug effects
  • Receptors, Nicotinic* / drug effects
  • Receptors, Nicotinic* / metabolism
  • Self Administration
  • Synaptic Transmission / drug effects
  • Synaptic Transmission / physiology
  • Xenopus laevis

Substances

  • Dopamine
  • Receptors, Nicotinic
  • Nicotine
  • Ibogaine
  • 18-methoxycoronaridine
  • Dopamine Plasma Membrane Transport Proteins
  • nicotinic receptor alpha6
  • Nicotinic Antagonists
  • Nicotinic Agonists